Skip to main content
Premium Trial:

Request an Annual Quote

Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

NEW YORK (GenomeWeb) – Resolution Bioscience said today that it is collaborating with Janssen to develop its Resolution HRD liquid biopsy test as a companion diagnostic for niraparib, a PARP inhibitor being investigated to treat patients with metastatic castration-resistant prostate cancer.

Resolution HRD is a blood-based, cell-free DNA assay that detects single nucleotide variants, copy number variants, and deletions in genes related to homologous recombination deficiency (HRD). The assay is currently being used to screen prostate cancer for HRD mutations and deletions as part of phase II and II clinical studies of niraparib in prostate cancer. Janssen has exclusive worldwide rights from Tesaro to develop niraparib for use in prostate cancer.

Resolution received a Breakthrough Device Designation from the US Food and Drug Administration for Resolution HRD last month.

"Resolution Bioscience is committed to partnering with leading pharmaceutical companies to develop diagnostic assays that may assist in bringing new therapies to market," Resolution Bioscience CEO Mark Li said in a statement. "We expect the Resolution HRD assay will enable Janssen to identify patients with prostate cancer who may benefit from niraparib therapy."

Resolution plans to seek approval for the assay as a companion diagnostic for niraparib in prostate cancer. If approved, the firm said the assay could be the first test to find gene deletions from cfDNA, as well as to distinguish between single copy and homozygous gene deletions through a blood draw.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.